[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Oct 2011

Lentigo Maligna: One Size Does Not Fit All

Author Affiliations

Author Affiliations: Multidisciplinary Melanoma Program, Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City.

Arch Dermatol. 2011;147(10):1211-1213. doi:10.1001/archdermatol.2011.234

The diagnosis and treatment of lentigo maligna (LM) present challenges to the dermatopathologist and clinician, who struggle to make an accurate diagnosis, devise a treatment plan appropriate to the age and health status of the patient, and determine when surgical margins are truly negative. All these issues create complexity when managing an increasingly common tumor.1 Because most LM lesions occur in cosmetically sensitive areas —usually on the head and neck2 —surgical morbidity is an unavoidable consequence of staged excisions with relatively large defects. When confronted with an ambiguous pathology report, such as “atypical junctional melanocytic hyperplasia with severe atypia on sun-damaged skin ” or “evolving melanoma in situ, ” the clinician is caught on the horns of a dilemma: is this LM or not? If so, what treatment approach strikes the appropriate balance between the relatively low risk of the tumor becoming invasive (if the LM began when the patient was 65 years old, the estimated lifetime risk is 3.3%)3 vs the morbidity of a large staged excision? When it comes to treatment, if ever there was a tumor for which one size does not fit all, it is LM.